Your browser is no longer supported. Please, upgrade your browser.
Cara Therapeutics, Inc.
Index- P/E142.52 EPS (ttm)0.11 Insider Own2.70% Shs Outstand50.06M Perf Week-0.13%
Market Cap778.36M Forward P/E- EPS next Y-1.23 Insider Trans-4.01% Shs Float43.32M Perf Month16.68%
Income8.40M PEG- EPS next Q-0.39 Inst Own63.80% Short Float8.93% Perf Quarter4.81%
Sales123.30M P/S6.31 EPS this Y107.00% Inst Trans-3.52% Short Ratio2.53 Perf Half Y-22.31%
Book/sh4.06 P/B3.76 EPS next Y37.20% ROA3.80% Target Price26.33 Perf Year3.25%
Cash/sh3.04 P/C5.02 EPS next 5Y- ROE4.10% 52W Range11.22 - 29.65 Perf YTD0.79%
Dividend- P/FCF50.22 EPS past 5Y16.80% ROI2.40% 52W High-48.56% Beta1.15
Dividend %- Quick Ratio10.80 Sales past 5Y104.20% Gross Margin- 52W Low35.92% ATR0.85
Employees80 Current Ratio10.80 Sales Q/Q2384.80% Oper. Margin- RSI (14)57.22 Volatility4.02% 6.62%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.70% Profit Margin6.80% Rel Volume1.09 Prev Close14.93
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout0.00% Avg Volume1.53M Price15.25
Recom1.90 SMA202.81% SMA5012.28% SMA200-8.61% Volume1,673,174 Change2.14%
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Sep-04-21 08:55AM  
Aug-27-21 05:33PM  
Aug-24-21 04:08PM  
Aug-23-21 07:06PM  
Aug-15-21 08:07AM  
Aug-11-21 10:22AM  
Aug-09-21 09:00PM  
Aug-04-21 07:04PM  
Aug-02-21 04:01PM  
Jul-29-21 03:53PM  
Jul-12-21 10:26AM  
Jun-11-21 07:30AM  
Jun-10-21 02:02AM  
May-29-21 06:41AM  
May-25-21 07:00AM  
May-23-21 06:30AM  
May-10-21 08:30PM  
May-06-21 04:01PM  
May-03-21 04:01PM  
Apr-29-21 11:33AM  
Apr-07-21 04:01PM  
Apr-06-21 10:59AM  
Apr-05-21 06:55PM  
Mar-31-21 07:00AM  
Mar-30-21 12:01PM  
Mar-29-21 04:58PM  
Mar-08-21 09:28AM  
Feb-26-21 08:01AM  
Feb-25-21 04:01PM  
Feb-24-21 10:13AM  
Feb-18-21 04:01PM  
Feb-10-21 12:38AM  
Feb-07-21 02:13PM  
Feb-03-21 03:21AM  
Jan-11-21 07:00AM  
Jan-08-21 08:56AM  
Jan-06-21 07:00AM  
Dec-28-20 07:00AM  
Dec-24-20 07:30AM  
Dec-22-20 04:05PM  
Dec-18-20 12:19AM  
Dec-02-20 07:00AM  
Nov-17-20 01:16PM  
Nov-12-20 05:42AM  
Nov-11-20 07:00AM  
Nov-09-20 09:00PM  
Nov-02-20 04:01PM  
Oct-27-20 04:05PM  
Oct-22-20 12:00PM  
Oct-21-20 04:01PM  
Oct-20-20 03:30PM  
Oct-16-20 11:01AM  
Oct-14-20 12:57PM  
Oct-11-20 08:55AM  
Oct-01-20 07:00AM  
Aug-27-20 09:55AM  
Aug-11-20 05:30PM  
Aug-10-20 06:05PM  
Aug-06-20 04:01PM  
Aug-03-20 04:01PM  
Jul-29-20 12:33PM  
Jul-13-20 02:47PM  
Jul-08-20 01:34PM  
Jun-30-20 07:00AM  
Jun-25-20 06:04PM  
Jun-17-20 07:00AM  
May-27-20 04:01PM  
May-15-20 11:00AM  
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHALMERS DEREK TPresident & CEOSep 07Sale15.4720,000309,400991,405Sep 09 04:48 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Aug 30Sale14.201,75924,97870,917Sep 01 06:09 PM
Reilly Thomas CharlesChief Financial OfficerAug 30Sale14.201,98228,1443,352Sep 01 06:08 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DAug 30Sale14.203,84754,627141,072Sep 01 06:07 PM
Goncalves JoanaChief Medical OfficerAug 30Sale14.202,11029,96247,900Sep 01 06:06 PM
CHALMERS DEREK TPresident & CEOAug 30Sale14.208,440119,8481,011,405Sep 01 06:04 PM
VOGELBAUM MARTINDirectorJun 07Sale13.058,640112,75220,160Jun 07 07:35 PM
Posner ChristopherDirectorJun 07Sale13.042,30430,04416,096Jun 07 07:33 PM
Ives Jeffrey L.DirectorJun 07Sale13.052,52032,88615,380Jun 07 07:25 PM
Goncalves JoanaChief Medical OfficerApr 21Sale27.633,00082,89043,610Apr 23 05:05 PM
Goncalves JoanaChief Medical OfficerMar 22Sale19.653,00058,95030,610Mar 24 05:55 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 05Sale17.983,35860,377119,319Mar 08 05:48 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Mar 05Sale17.983,09055,55851,342Mar 08 05:47 PM
Goncalves JoanaChief Medical OfficerMar 05Sale17.983,09355,61233,610Mar 08 05:45 PM
CHALMERS DEREK TPresident & CEOMar 05Sale17.983,10355,792950,511Mar 08 05:44 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Feb 25Sale19.334,00477,39744,432Feb 25 09:06 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DFeb 25Sale19.335,00396,708112,677Feb 25 09:05 PM
Goncalves JoanaChief Medical OfficerFeb 25Sale19.333,37265,18126,703Feb 25 09:04 PM
CHALMERS DEREK TPresident & CEOFeb 25Sale19.3311,729226,722943,614Feb 25 09:02 PM
Goncalves JoanaChief Medical OfficerFeb 22Sale19.732,00039,46026,075Feb 24 05:02 PM
Goncalves JoanaChief Medical OfficerJan 21Sale20.122,00040,24028,075Jan 25 05:32 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Dec 30Sale15.301,94629,77442,436Dec 30 06:16 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DDec 30Sale15.302,81243,024109,680Dec 30 06:15 PM
Goncalves JoanaChief Medical OfficerDec 30Sale15.301,29819,85930,075Dec 30 06:14 PM
CHALMERS DEREK TPresident & CEODec 30Sale15.306,07892,993936,593Dec 30 06:12 PM
CHALMERS DEREK TPresident & CEODec 28Sale16.005,00080,000942,671Dec 29 06:41 PM
Goncalves JoanaChief Medical OfficerDec 21Sale15.002,00030,00027,373Dec 23 07:11 PM
CHALMERS DEREK TPresident & CEODec 16Sale14.955,00074,750928,921Dec 18 04:58 PM
CHALMERS DEREK TPresident & CEODec 10Sale15.297,500114,675933,921Dec 11 08:32 PM
Goncalves JoanaChief Medical OfficerNov 23Sale15.312,00030,62029,373Nov 25 04:48 PM
Posner ChristopherDirectorNov 19Sale15.822,00031,63811,200Nov 23 08:28 PM
CHALMERS DEREK TPresident & CEONov 17Sale16.0011,799188,784941,421Nov 19 05:29 PM
VOGELBAUM MARTINDirectorNov 17Sale16.096,00096,54014,400Nov 19 05:30 PM
Goncalves JoanaChief Medical OfficerNov 10Sale15.002,00030,00031,373Nov 13 05:39 PM
Goncalves JoanaChief Medical OfficerOct 20Sale15.002,00030,00033,373Oct 22 06:00 PM